Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.
Lancet Respir Med
; 11(4): 329-340, 2023 04.
Article
en En
| MEDLINE
| ID: mdl-36343646
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Fibrosis Quística
Tipo de estudio:
Clinical_trials
/
Guideline
/
Prognostic_studies
Límite:
Humans
Idioma:
En
Año:
2023
Tipo del documento:
Article